Discriminating patients with early-stage breast cancer from benign lesions by detection of oxidative DNA damage biomarker in urine
| Autor: | Jiekai Yu, Cheng Guo, Shu Zheng, Xiaoji Cao, Mengzhe Guo, Xiaofen Li, Cong Xie, Minfeng Ye, Fei Xu, Ying Yuan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Urinary system Urine 03 medical and health sciences 0302 clinical medicine Breast cancer breast cancer Internal medicine Medicine Mammography Stage (cooking) mass spectrometry Cancer prevention medicine.diagnostic_test benign lesion business.industry Cancer medicine.disease urine Surgery 030104 developmental biology Oncology 030220 oncology & carcinogenesis Biomarker (medicine) biomarker business Research Paper |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | // Cheng Guo 1, * , Xiaofen Li 1, * , Minfeng Ye 1, 2, * , Fei Xu 1 , Jiekai Yu 1 , Cong Xie 3 , Xiaoji Cao 3 , Mengzhe Guo 4 , Ying Yuan 5 and Shu Zheng 1 1 Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China 2 Department of Gastrointestinal Surgery, Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, China 3 College of Chemical Engineering, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, China 4 Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical College, Xuzhou, Jiangsu 221004, China 5 Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China * These authors have contributed equally to this work Correspondence to: Cheng Guo, email: cheng_guo@zju.edu.cn Mengzhe Guo, email: guomengzhe@xzhmu.edu.cn Shu Zheng, email: zhengshu@zju.edu.cn Keywords: breast cancer, benign lesion, biomarker, urine, mass spectrometry Received: January 11, 2017 Accepted: April 12, 2017 Published: May 12, 2017 ABSTRACT Breast cancer is one of the most commonly diagnosed and death-related cancers in women worldwide. Mammography is routinely used for screening and invasive examinations such as painful tissue biopsies were recommended for patients with abnormal screening outcomes. However, a considerable proportion of these cases turn out to be benign lesions. Thus, novel non-invasive approach for discriminating breast cancer from benign lesions is desirable. Herein, we applied a high-throughput ultra performance liquid chromatography-electrospray ionization tandem mass spectrometry (UPLC-ESI-MS/MS) analysis to determine the oxidative DNA damage biomarker, 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG) in urine samples from 60 patients with early-stage breast cancer (stage I, II), 51 patients with benign breast diseases and 73 healthy volunteers. We demonstrated that the concentration of urinary 8-oxodG in patients with early-stage breast cancer was significantly higher not only than that in healthy controls, but also than that in patients with benign breast diseases, whereas no significant difference of urinary 8-oxodG level was observed between benign breast diseases group and healthy control group. Moreover, there was significant difference between early-stage breast cancer group and non-cancerous group which consisted of benign breast diseases patients and healthy controls. Besides, logistic regression analysis and receiver operator characteristic (ROC) curve analysis were also performed. Our findings indicate that the marked increase of 8-oxodG in urine may serve as a potential biomarker for the risk estimation, early screening and detection of breast cancer, particularly for discriminating early-stage breast cancer from benign lesions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|